Letrozole for Fertility: Ovulation Induction and Frozen Embryo Transfer
Key Takeaways
Letrozole's best-supported fertility use is inducing ovulation: in anovulatory PCOS it leads to more live births than clomiphene and is the first-line medicine. It does not offer the same advantage in unexplained infertility. Before a frozen embryo transfer, a letrozole cycle is a reasonable option for some patients with irregular ovulation, but randomized trials show no live-birth advantage over a programmed cycle.
Key evidence: 2023 International PCOS Guideline (Fertility and Sterility) Cochrane review of letrozole for ovulation induction in PCOS 2026 meta-analysis of randomized letrozole FET trials
Frozen embryo transfer with letrozole
What letrozole actually does
Letrozole temporarily blocks aromatase, lowering estrogen early in the cycle. The pituitary may then release more follicle-stimulating hormone (FSH), helping a follicle grow and ovulate. That effect is used in two different ways in fertility care:
- to induce ovulation in women who do not ovulate regularly, so that pregnancy can happen through intercourse or insemination
- to prepare the uterus for a frozen embryo transfer (FET), where the ovulation creates the body’s own estrogen, progesterone and corpus luteum. This differs from a programmed cycle, in which estrogen and progesterone are prescribed.
The evidence for these two uses is very different, so they are discussed separately below. In FET, the mechanism explains why the option is biologically plausible; it does not prove that the endometrium will be more receptive or that live birth will be more likely.
Letrozole to induce ovulation
For women with polycystic ovary syndrome (PCOS, now also called PMOS) who do not ovulate and have no other major infertility factor, the 2023 International PCOS Guideline names letrozole the first-line medicine to induce ovulation. The 2023 International PCOS Guideline
How well it works
In women with anovulatory PCOS, the 2022 Cochrane review of randomized trials found more live births with letrozole than with clomiphene, with high-certainty evidence. Where about 20 in 100 women would have a live birth with clomiphene, about 27 to 35 in 100 would with letrozole. Ovarian hyperstimulation was equally rare with both (about 0.5%), and multiple pregnancy was uncommon with both (1.6% with letrozole, 2.2% with clomiphene). The 2022 Cochrane review In the largest single trial, 750 women with PCOS were treated for up to five cycles: 27.5% had a live birth with letrozole and 19.1% with clomiphene, and ovulation occurred in 61.7% versus 48.3% of treatment cycles. The PPCOS II trial
These figures describe groups of women whose main problem is absent ovulation. They are not a personal success rate: age, tubal health, sperm quality, weight and the number of cycles tried all change the chance.
The picture changes when ovulation is already regular. In a randomized trial of 900 ovulatory women with unexplained infertility, letrozole led to fewer pregnancies and live births than gonadotropin injections and was not better than clomiphene, although it caused fewer multiple pregnancies than injections. The unexplained-infertility trial Letrozole is therefore not a stronger option for unexplained infertility simply because it helps in PCOS.
What a treatment cycle involves
Letrozole is taken as a short tablet course early in the menstrual cycle. The starting dose and any increase are set by the fertility specialist from the previous response; Dr. Aksoy describes his usual approach in the questions below, and it is not a schedule to follow without your own doctor. Ultrasound tracking shows whether a follicle is growing, helps time intercourse or insemination, and detects a response with several mature follicles, which raises the chance of twins.
When to change the plan
In clinical input recorded for the site’s PCOS guide (2026-09-21), Dr. Aksoy said he generally uses letrozole first for PCOS-related anovulation. He reconsiders the plan when follicles do not develop despite an appropriate dose and monitoring, when pregnancy has not occurred after several ovulatory cycles, when age creates time pressure, when there is a significant metabolic problem, or when the couple does not want to prolong treatment. Gonadotropin injections are a second-line option when close ultrasound monitoring is possible, and IVF may be considered earlier when age or ovarian reserve makes losing several months inappropriate. The PCOS guide covers these steps in more detail.
Before a frozen embryo transfer: where the evidence is clearest
Anovulatory PCOS or irregular ovulation
Letrozole is a first-line pharmacological ovulation-induction treatment for infertile anovulatory adults with PCOS when there is no other infertility factor that changes the plan. The 2023 International PCOS Guideline supports that use. The recommendation is about restoring ovulation—not about proving a separate implantation-enhancing effect in FET.
A 2025 systematic review and meta-analysis of PCOS or oligo-anovulatory FET included 15 observational studies and two randomized trials. It found a modest apparent live-birth advantage, but every outcome was judged low-certainty; the randomized trial reporting live birth did not confirm an advantage. The Human Reproduction Update review therefore supports “a possible alternative,” not “a proven better protocol.” An earlier randomized trial of 120 women with PCOS, which combined letrozole with gonadotropin injections, also found similar implantation, clinical and ongoing pregnancy rates. The 2020 trial
People who already ovulate regularly
Evidence is less persuasive when ovulation is already regular. Across frozen transfer trials, the 2020 Cochrane review found low-quality evidence that a stimulated cycle (FSH, letrozole or clomiphene) may raise clinical pregnancy compared with a programmed cycle; for live birth with letrozole, only one small trial was available and the result was uncertain. The 2020 Cochrane review In a randomized trial of 167 women with regular ovulatory cycles, clinical pregnancy was 38.7% with letrozole and 25.3% with a programmed cycle. The difference was not statistically significant (P = 0.06), and women whose lining did not reach the target thickness were excluded. The 2019 trial A large retrospective cohort of ovulatory patients with unexplained infertility reported more live births with letrozole than with a natural cycle, but a retrospective comparison cannot rule out differences between the groups. The 2022 cohort A molecular marker or endometrial-thickness change is an intermediate finding; it is not the same as a higher live-birth rate.
For a patient who already ovulates, a natural or modified-natural FET cycle is also a separate option—not simply a choice between letrozole and a programmed cycle. In a 2026 multicentre randomized trial of 4,376 ovulatory women, natural and programmed cycles produced similar healthy live-birth rates; pre-eclampsia was lower with natural ovulation, but cycle cancellation was more common. The BMJ trial was not a letrozole trial, so it informs the wider protocol discussion rather than proving that letrozole is preferable.
What can change the choice in practice
Dr. Aksoy’s clinical input places the emphasis on a practical question: can the patient reliably develop one dominant follicle and a corpus luteum with letrozole? A previous letrozole response, reliable ultrasound and hormone monitoring, and a clinical reason to avoid a corpus-luteum-free programmed cycle may favor stimulation. The 2025 review also found lower odds of hypertensive disorders with letrozole-stimulated FET, although the certainty of that evidence was low and a 2026 analysis limited to randomized trials found no difference. Thrombotic risk is a patient-specific clinical consideration here; this review evaluated hypertensive disorders, not proof that letrozole prevents thrombosis. Human Reproduction Update
Current randomized evidence does not show a consistent live-birth advantage. A 420-participant trial found nearly identical live-birth rates, and a 2025 trial of 200 patients found no statistically significant difference in clinical pregnancy. The 2023 randomized trial and the 2025 randomized trial support treating letrozole as an individualized option rather than an automatic choice for every patient with PCOS. A multicentre 2025 randomized trial of 155 women with PCOS likewise found no significant difference in clinical pregnancy, live birth or reported obstetric outcomes between letrozole and programmed preparation. That trial supports the same cautious interpretation. A small 2026 randomized trial of 100 participants, in which the stimulation arm combined letrozole with FSH, reported more clinical pregnancies; follow-up ended before birth, so it does not show a live-birth advantage. The 2026 trial
The most recent pooled analysis points the same way. A 2026 meta-analysis limited to four randomized trials (891 women with PCOS, now also called PMOS) found no difference in live birth, clinical pregnancy, miscarriage, hypertensive disorders or cycle cancellation between letrozole-based and programmed preparation. The 2026 meta-analysis
Gestational diabetes is the open question. The 2023 trial reported more gestational diabetes with letrozole (14.6% vs 5.6%, a borderline result) and a difference in singleton birth weight. The 2025 meta-analysis, which relied mostly on observational studies, found no overall difference. The 2026 randomized-trial analysis, however, found less gestational diabetes with programmed cycles in the two trials that reported it; its authors call this finding hypothesis-generating. The 2026 meta-analysis Obstetric advantages of letrozole should therefore not be treated as settled.
Letrozole may be a poor fit after inadequate follicular development or repeated cycle cancellation, repeated thin endometrium, uncontrolled multifollicular response, unreliable ovulation timing, marked hypogonadotropic or hypoestrogenic states, or when the patient cannot complete monitoring. A programmed cycle may be more practical when the transfer date must be scheduled precisely.
What the decision depends on
A clinician may consider:
- whether ovulation is regular and predictable
- whether the cycle can be monitored with ultrasound and, when needed, hormone tests
- previous endometrial thickness and cycle cancellation
- uterine-cavity abnormalities or hydrosalpinx
- embryo quality and transfer timing
- whether predictable scheduling is important
- metabolic and pregnancy-risk issues related to PCOS
The choice is not made from lining thickness alone. A thin lining, a cavity problem, embryo quality, or progesterone timing may require a different evaluation.
What a letrozole FET cycle involves
The exact plan varies. It usually means early-cycle medication, ultrasound monitoring of follicle growth and endometrium, confirmation and timing of ovulation, and carefully timed progesterone and embryo transfer. Some cycles are cancelled or changed if the follicle, lining or timing is not suitable.
This is why letrozole should not be treated as a self-directed add-on or as a substitute for investigating repeated implantation failure.
Safety and practical limits
Letrozole use for fertility is off-label in many countries. A pregnancy should be excluded before treatment; letrozole should not be taken during an established pregnancy. The 2023 International PCOS Guideline and the official DailyMed label describe these boundaries.
In the two large ovulation-induction trials, overall congenital anomaly rates did not differ significantly between letrozole and the comparison treatments; those trials were not large enough to rule out rare effects. PPCOS II and the unexplained-infertility trial
Short courses can still cause side effects such as headache, fatigue, dizziness or hot flushes. Your clinician should review other medicines, liver disease, ovarian response and the risk of multiple pregnancy. Do not start, stop or change the dose from an online protocol.
What it cannot fix
Letrozole cannot open blocked tubes or overcome a severe sperm problem when it is used to induce ovulation. In FET, it cannot correct poor embryo quality, a uterine-cavity abnormality, hydrosalpinx, incorrectly timed progesterone exposure, or every cause of repeated implantation failure. It cannot guarantee implantation, pregnancy or live birth.
A practical way to frame the conversation
Ask your fertility team:
- Do I ovulate regularly, and is that confirmed?
- What problem are we trying to solve: ovulation, lining, scheduling, or a previous failed transfer?
- What evidence applies to my patient group?
- How will follicle growth, endometrium and progesterone timing be monitored?
- What would make us change or cancel the cycle?
The best protocol is the one that matches the actual problem, not the one with the most attractive mechanism.
Frequently Asked Questions for Dr. Aksoy
Does letrozole thin or thicken the uterine lining?
The idea that letrozole thins the lining is not quite right. On the days it is taken, it lowers estrogen production for a short time. That stimulates the ovaries: a follicle develops, and the growing follicle starts producing estrogen again, so the lining can develop too.
Letrozole should not be confused with clomiphene, which can affect the lining unfavourably and thin it in some women. This effect is much less common with letrozole. Some studies have even found a thicker lining with letrozole than with clomiphene. A 2023 meta-analysis of 50 trials That does not mean letrozole will thicken the lining in every woman.
I use letrozole mainly to achieve egg development. I may consider it for some patients with a thin lining, but it is not a medicine I recommend to everyone just to thicken the endometrium. What matters to me is not only how many millimetres the lining measures, but whether it has been prepared appropriately alongside the egg’s development.
Does letrozole really help you get pregnant, and who does it help?
Yes, in the right patient letrozole can increase the chance of pregnancy. But it does not help everyone with a fertility problem in the same way.
One of the groups I use it for most is women who do not ovulate regularly because of polycystic ovary syndrome. In these patients it can restore ovulation and so increase the chance of a natural pregnancy; current guidelines list it as a first choice for women with PCOS who do not ovulate and have no other infertility factor. I sometimes also use it in couples with unexplained infertility, during insemination (IUI) treatment, to develop one or a few follicles.
However, giving letrozole to a woman who ovulates regularly, has open tubes and whose partner’s semen analysis is normal, simply so that she gets pregnant faster, has not been shown to bring a clear benefit. NICE guideline NG257 If both tubes are blocked or there is a severe sperm problem, developing an egg with letrozole alone does not solve the problem.
I do not see letrozole as a medicine that strengthens the ovaries or improves egg quality. Its basic job is to bring about ovulation or, as part of treatment, to stimulate follicle development. I also pay attention to ultrasound monitoring while it is used, because sometimes more than one egg develops and the risk of twins rises. In short, what decides whether letrozole will help is why the patient is not getting pregnant. In the right patient it can be quite effective, but it is not a solution to every fertility problem.
Do you use letrozole for infertility caused by endometriosis?
I do not give letrozole to every patient diagnosed with endometriosis, because we do not have enough scientific evidence that letrozole treats endometriosis and so increases the chance of pregnancy. ESHRE endometriosis guideline For example, in a woman with an endometrioma (a “chocolate cyst”) who ovulates regularly, I would not consider letrozole necessary just because endometriosis is present.
However, if we are planning insemination for a couple with mild endometriosis, open tubes and suitable semen values, letrozole can be one of the options to stimulate egg development. Even so, there is no strong evidence that letrozole is better than other stimulating medicines specifically in women with endometriosis. If the disease is advanced, the tubes are damaged or ovarian reserve is reduced, I may find it more appropriate to move to IVF than to direct the patient to months of attempts with medication.
There are special situations in which letrozole is used together with other hormone medicines to treat endometriosis-related pain. That use should not be confused with the short letrozole course we use to achieve pregnancy. My approach is to treat the reason the woman cannot get pregnant, not the diagnosis of endometriosis. If the problem is not ovulation, I do not think giving letrozole alone will increase the chance of pregnancy.
How is letrozole taken?
Letrozole is a medicine we use to bring about ovulation or to support egg development. But I do not start every patient on the same dose or on the same days. I first look at the woman’s cycle pattern, the state of her ovaries and whether she has had treatment before.
It is usually started on the second or third day of the period and taken for five days, for example on days 2–6 or 3–7 of the cycle. The starting dose is most often 2.5 mg a day. If the ovaries do not respond well enough, we can raise the dose in later cycles to 5 or 7.5 mg, but I make that decision according to the patient’s response. The PPCOS II trial used the same starting dose and the same maximum.
For me, it is not only about taking the medicine but also about seeing how the ovaries respond. That is why I prefer an ultrasound check, especially in the first treatment cycle: I look at how many follicles have developed, how large they are and what the lining looks like. Our aim is not to grow as many eggs as possible, but to obtain a suitable number of mature follicles for pregnancy while keeping the risk of multiple pregnancy low.
Letrozole can cause hot flushes, headache, nausea or dizziness in some women. Because it must not be used during pregnancy, the possibility of pregnancy should be ruled out before treatment starts. Using the medicine without a doctor’s advice, or increasing the dose on your own, is not right, especially for women with polycystic ovaries. If more than one follicle develops, there can be a risk of twins or a higher-order multiple pregnancy.
When does ovulation happen after letrozole?
One of the questions women taking letrozole ask most often is how many days after the last tablet they will ovulate.
Ovulation most often happens about 5–10 days after the last tablet. For a woman who took the medicine on days 2–6 of her cycle, for example, ovulation may occur roughly between days 11 and 16. But this is not a fixed calendar: some women ovulate earlier, some later, and some patients do not ovulate at all on the first dose.
That is why I do not rely on a calendar count alone. Especially in the first treatment cycle, I prefer to check egg development by ultrasound around days 10–12 of the cycle; the size of the follicle lets us estimate better when ovulation may happen. Home ovulation tests can help, but in women with polycystic ovaries they can sometimes give misleading results. When needed, we can plan the timing of ovulation more precisely with a trigger injection; ovulation is then usually expected about 36–40 hours after the injection.
For couples trying to conceive naturally, I recommend intercourse every one or two days during the expected ovulation window. Having intercourse every day, or trying to catch a particular hour, is not necessary. When I want to be sure that ovulation has really happened, I may measure progesterone about seven days after the expected ovulation.
What matters to me is not assuming that every woman taking letrozole will ovulate on the same day. When I assess the effect of the medicine, I look at how the ovaries respond more than at the calendar.
Sources
- Teede HJ et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and Sterility. 2023;120(4):767–793. doi:10.1016/j.fertnstert.2023.07.025. Full text
- Bülow et al. Reproductive outcomes after letrozole-stimulated versus artificial frozen-thawed embryo transfer cycles in women with PCOS and/or oligo-anovulation: a systematic review and meta-analysis. Human Reproduction Update. 2025;31(5):445–463. doi:10.1093/humupd/dmaf011. PubMed
- Glujovsky D et al. Endometrial preparation for women undergoing embryo transfer with frozen embryos or embryos derived from donor oocytes. Cochrane Database of Systematic Reviews. 2020;10:CD006359. doi:10.1002/14651858.CD006359.pub3. Full review
- Hosseini-Najarkolaei et al. The effect of letrozole versus artificial hormonal endometrial preparation on pregnancy outcome after frozen-thawed embryo transfer cycles: a randomized clinical trial. Reproductive Biology and Endocrinology. 2020;18:115. doi:10.1186/s12958-020-00675-z. Full article
- Yuan et al. Letrozole during frozen embryo transfer in women with polycystic ovarian syndrome: a randomized controlled trial. Obstetrics & Gynecology. 2023;142(5):1087–1095. doi:10.1097/AOG.0000000000005367. PubMed
- Jiang et al. Letrozole-stimulated cycles versus hormone replacement treatment cycles for frozen embryo transfer in women with polycystic ovary syndrome: a prospective randomized controlled trial. Journal of Assisted Reproduction and Genetics. 2025;42(6):1907–1915. doi:10.1007/s10815-025-03500-x. PubMed
- Xie et al. Letrozole ovulation regimen for frozen-thawed embryo transfer in women with polycystic ovary syndrome: a multicentre randomised controlled trial. Reproductive Biology and Endocrinology. 2025;23:103. doi:10.1186/s12958-025-01432-w. Full article
- Wei et al. Natural ovulation versus programmed regimens before frozen embryo transfer in ovulatory women: multicentre, randomised clinical trial. BMJ. 2026;392:e087045. doi:10.1136/bmj-2025-087045. Full article
- Erden M et al. Letrozole-based stimulation versus programmed cycle for frozen embryo transfer in women with polyendocrine metabolic ovarian syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive BioMedicine Online. 2026;53(6):105967. doi:10.1016/j.rbmo.2026.105967. PubMed
- Hamdi et al. Comparison of frozen embryo transfer outcomes in hormonal versus mild stimulation protocols in polycystic ovary syndrome women: a randomized controlled trial. International Journal of Reproductive BioMedicine. 2026;23(12):995–1006. doi:10.18502/ijrm.v23i12.20712. PubMed
- Ezoe K et al. Letrozole-induced endometrial preparation improved the pregnancy outcomes after frozen blastocyst transfer compared to the natural cycle: a retrospective cohort study. BMC Pregnancy and Childbirth. 2022;22:824. doi:10.1186/s12884-022-05174-0. Full article
- Franik S et al. Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2022;9:CD010287. doi:10.1002/14651858.CD010287.pub4. Full review
- Legro RS et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. New England Journal of Medicine. 2014;371(2):119–129. doi:10.1056/NEJMoa1313517. PubMed
- Diamond MP et al. Letrozole, gonadotropin, or clomiphene for unexplained infertility. New England Journal of Medicine. 2015;373(13):1230–1240. doi:10.1056/NEJMoa1414827. PubMed
- Abu-Zaid A et al. Comparison of letrozole and clomiphene citrate in pregnancy outcomes in patients with polycystic ovary syndrome: a systematic review and meta-analysis. Reproductive Sciences. 2024;31(4):883–905. doi:10.1007/s43032-023-01404-8. PubMed
- Becker CM et al. ESHRE guideline: endometriosis. Human Reproduction Open. 2022;2022(2):hoac009. doi:10.1093/hropen/hoac009. Full text
- National Institute for Health and Care Excellence. Fertility problems: assessment and treatment (NG257), recommendations 1.38.1–1.38.3. 2026. Guideline
- U.S. National Library of Medicine. Letrozole prescribing information. DailyMed label
- Samsami et al. Frozen embryo transfer: endometrial preparation by letrozole versus hormone replacement cycle: a randomized clinical trial. International Journal of Reproductive BioMedicine. 2019;17(12):915–922. doi:10.18502/ijrm.v17i12.5793. PubMed
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.